ReviewHepatology international2025
Do the therapeutic vaccines hold hope for the treatment of hepatitis B?
Review in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advancing Global Hepatitis B Elimination: The Case for Using Maize as a Low-Cost, Heat-Stable, and Scalable Oral Vaccine.Vaccines · 2026Review
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChronic hepatitis B (CHB) is a global disease that can induce severe conditions such as cirrhosis and liver cancer, posing a serious threat to human health. The low functional cure rate of existing antiviral treatment drugs is primarily due to the dysfunctional immune response in CHB patients and the difficulty in clearing intrahepatic cccDNA.
methodsThis article reviews the latest progress in the research on therapeutic vaccines for CHB, to analyze and discuss the potential impact of current achievements and to outline the prospects for future research, exploring therapeutic strategies for the functional cure of CHB.
resultsTherapeutic vaccines are anticipated to activate specific immune responses in CHB patients, break the mechanisms of immune tolerance, and exhibit significant potential in maintaining long-term immune activity. Several therapeutic vaccines have already demonstrated promising therapeutic effects.
conclusionsTherapeutic vaccines are of great significance in the field of CHB treatment. Current research achievements provide strong support for their application, while combined therapy offers new ideas and hope for future treatment directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.